Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | SKylaRk trial update: Isa-KRd in newly diagnosed, transplant-eligible multiple myeloma

In this video, Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses findings from the SKylaRk trial (NCT04430894), which is evaluating the safety and efficacy of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with transplant-eligible, newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.